BioAmber Signs Take-or-Pay Contract For Three Bio-Succinic Acid Plants

Vinmar commitment is for 210,000 tons of succinic acid per year when three plants operational

• Contract guarantees sale of 10,000 tons per year for 15 years from Sarnia plant in construction
• 50% of Sarnia capacity is under take-or-pay, with total contracted demand exceeding capacity
• Previously announced 100,000 ton per year BDO plant will be expanded to also produce 70,000 tons per year of succinic acid, with Vinmar off-taking 100% of the BDO produced and 70% of the bio-succinic acid produced for 15 years
• Vinmar also commits to off-take 75% of the production from a new, third bio-succinic acid plant with 200,000 MT per year capacity that BioAmber currently plans to startup in 2020
• Vinmar commits to a 10% or greater equity investment in each of the next two plants

Endo and BioDelivery Sciences announce positive top-line results from the Phase III clinical trial of BEMA® buprenorphine in opioid-experienced patients with chronic pain

- Pre-NDA meeting scheduled with FDA in July

DUBLIN and RALEIGH, N.C., July 7, 2014 -- Endo Pharmaceuticals Inc., a subsidiary of Endo International plc (ENDP) (ENL.TO), and BioDelivery Sciences International, Inc. (BDSI) announced today positive top-line results from its pivotal Phase III efficacy study of BEMA buprenorphine in opioid-experienced patients. BEMA buprenorphine is being developed for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate in both patients who are opioid naive and opioid experienced. 

GlobeImmune Announces Pricing of Initial Public Offering

LOUISVILLE, Colo., July 1, 2014 -- GlobeImmune, Inc. (GBIM), today announced the pricing of its initial public offering of 1,500,000 shares of its common stock at a price to the public of $10.00 per share. The gross proceeds to GlobeImmune from the initial public offering are expected to be $15,000,000, before underwriting discounts and commissions and other offering expenses. In addition, GlobeImmune has granted the underwriter a 45-day option to purchase up to 225,000 additional shares of common stock from GlobeImmune to cover over-allotments, if any. GlobeImmune's common stock has been approved for listing on the NASDAQ Capital Market and is expected to begin trading tomorrow under the symbol "GBIM."

IGI Laboratories Added To The Russell 3000 Index

BUENA, N.J., June 30, 2014- IGI Laboratories, Inc. (NYSE MKT: IG; IGI or the Company), a specialty generic topical pharmaceutical company, has been added as a member of the broad-market Russell 3000® Index after the equity markets closed on June 27 as Russell Investments reconstituted its comprehensive family of global indexes.

Annual reconstitution of Russell's U.S. indexes captures the 4,000 largest U.S. stocks as of the end of May, ranking them by total market capitalization. Membership in the Russell 3000, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. Russell determines membership for its equity indexes primarily by objective, market-capitalization rankings and style attributes.